Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | MAOB | P27338 | 5/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | CTSV | O60911 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28317001 | 0.79 | MAOB (0.79) | MAPTMAOBMAOAFFAR1MEN1 | |
| SCHEMBL4606396 | 0.76 | ALDH1A1 (0.59) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL28966940 | 0.75 | ALDH1A1 (0.60) | MAOBCTSVCTSLMEN1KMT2A | |
| SCHEMBL10990654 | 0.74 | MAOB (0.72) | MAPTMAOBMAOAL3MBTL1 | |
| SCHEMBL12763816 | 0.73 | MEN1 (0.56) | MAPTMAOBMAOACTSVCTSL | |
| SCHEMBL28547278 | 0.73 | MAOB (0.70) | MAPTMAOBMAOAFFAR1MEN1 | |
| SCHEMBL27792404 | 0.73 | MEN1 (0.70) | MAPTMAOBMAOACTSVCTSL | |
| SCHEMBL17554366 | 0.73 | MAOB (0.73) | MAPTMAOBMAOAFFAR1MEN1 | |
| SCHEMBL10991540 | 0.73 | MAOB (0.70) | MAOBMAOAFFAR1 | |
| SCHEMBL10987251 | 0.73 | MAOB (0.69) | MAOBMAOAFFAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720825-B1 | ANTHRANILIC ACID DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE AS DHODH INHIBITORS | ACTIVE BIOTECH AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| EP-1720825-A1 | NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF | Active Biotech AB (SE) | 2006-11-15 | — | — | EP | disclosed |
| US-7074831-B2 | Compounds, methods for their preparation and use thereof | ACTIVE BIOTECH AB (SE) | 2006-07-11 | — | — | US | disclosed |
| US-20050187297-A1 | New compounds, methods for their preparation and use thereof | ACTIVE BIOTECH AB (SE) | 2005-08-25 | — | — | US | disclosed |
| WO-2005075410-A1 | NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF | ACTIVE BIOTECH AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187297-A1 | New compounds, methods for their preparation and use thereof | MALT1, TPMT, FUCA1 | MAPT 3698/4885MAOB 1445/4885MAOA 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.